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Purpose: To find out the possible role of 1,25(OH)2 vitamin D3 [1,25(OH)2D3] and 
parathyroid hormone (PTH) as intrinsic factors in urinary calcium stone formers 
(SFs), we investigated their relationship with serum and urinary biochemical pa-
rameters. Materials and Methods: A total of 326 calcium SFs (male: 204, female: 
122) were enrolled and underwent outpatient metabolic evaluations including 
1,25(OH)2D3 and PTH as well as serum and 24-hour urinary biochemical parame-
ters. As control, 163 age- and sex-matched (2:1) individuals (non-SFs) who have 
never urinary stone episode were included. Results: 1,25(OH)2D3 level was posi-
tively correlated with urinary calcium excretion (r=0.347, p<0.001). The hyper-
calciuric group and recurrent SFs had higher serum 1,25(OH)2D3 levels than the 
normocalciuric group (p<0.001) and first SFs (p=0.050). In the adjusted multiple 
linear regression analysis, serum 1,25(OH)2D3 level (β=0.259, p<0.001) and se-
rum PTH level (β=-0.160, p<0.001) were significantly correlated with urinary 
calcium excretion. The patients in highest tertile of 1,25(OH)2D3 had a more than 
3.1 fold risk of hypercalciuria than those in the lowest tertile (odds ratio=3.14, 
95% confidence interval: 1.431--6.888, p=0.004). No correlation was observed be-
tween PTH and 1,25(OH)2D3 (R=0.005, p=0.929) in calcium SFs, while a negative 
correlation was found in controls (R=-0.269, p=0.001). Conclusion: 1,25(OH)2D3 
was closely correlated with urinary calcium excretion, and high 1,25(OH)2D3 lev-
els were detected in the hypercalciuric group and in recurrent SFs. However, 
1,25(OH)2D3 was not correlated with PTH in calcium SFs. These findings sug-
gest that 1,25(OH)2D3 might be important intrinsic factor for altered calcium reg-
ulation in SFs.
Key Words:   1,25-dihydroxy-vitamin D3, calcium, parathyroid hormone, urolithi-
asis
INTRODUCTION
The incidence of urinary stone formation has been increasing recently, and the life-
time risk of stone formation is estimated at 5--12% in Europe and the USA.1-3 Envi-
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noradiometric assay with an ELSA-PTH kit (CIS Bio Inter-
national, Paris, France), and 1,25(OH)2D3 levels were also 
measured with a radioimmunoassay with a 1,25(OH)2D3 
RIA kit (Immunodiagnostic Systems Ltd., Boldon Colliery, 
Tyne & Wear, UK). The metabolic evaluation was per-
formed at least 4--6 weeks after returning to their normal 
life. SFs were advised to continue their usual diet, and none 
were placed on a low calcium diet or preventive medications. 
Patients were divided into two groups according to urinary 
calcium excretion (hypercalciuria vs. normocalciuria) and 
the prior stone episode (first time vs. recurrent), respective-
ly, and the clinical and laboratory characteristics of each 
group were compared. Hypercalciuria was defined as 24 h 
urinary calcium excretion of more than 300 mg per 24 hour 
in men and 250 mg per 24 hour in women. Hypercalciuric 
SFs and normocalciuric SFs were 19.9% (65/326) and 
80.1% (261/326), while the fractions of first SFs and recur-
rent SFs were 57.1% and 42.9%, respectively (total 324 
patents were analyzed due to 2 missing values). To com-
pare 1,25(OH)2D3 and PTH levels between calcium SFs 
and controls, 163 age- and sex-matched controls were in-
cluded.
Data analysis
Clinical characteristics, serum laboratory parameters in-
cluding PTH and 1,25(OH)2D3, and urinary biochemical 
parameters were compared in each group. The correlation 
between PTH or 1,25(OH)2D3 and serum and urinary pa-
rameters was assessed by the Spearman correlation test. 
The relationship between PTH and 1,25(OH)2D3 in calcium 
SFs and controls was assessed by the linear regression test. 
The differences in serum and urinary metabolites between 
subgroups were assessed by the Student’s t-test. Multiple 
linear regression analysis was performed to evaluate the as-
sociation between 24 h urinary calcium excretion and serum 
1,25(OH)2D3 or PTH after adjusting for the effects of other 
parameters. The logistic regression was carried out to identi-
fy the association between hypercalciuria and tertiles of se-
rum 1,25(OH)2D3. Dependent variable was the hypercalci-
uria; independent variable was tertile of serum 1,25(OH)2D3. 
Tertile cut-off points were determined on variable distribu-
tion of patients in the full study group. Odds ratios (ORs) 
and 95% confidential intervals (CIs) were estimated using 
logistic regression models. Statistical analysis was per-
formed using SPSS 19.0 software (SPSS Inc., Chicago, IL, 
USA). A p-value less than 0.05 was considered statistically 
significant.
ronmental, genetic, nutritional, intrinsic, anatomic and meta-
bolic factors contribute to urinary stone formation.4-8 
Hypercalciuria, regardless of its underlying mechanism, is 
the most common metabolic abnormality in patients with cal-
cium stones.9,10 Calciuria is a net loss of calcium in the urine 
after renal reabsorption and the final result of numerous regu-
latory processes.11 Parathyroid hormone (PTH) and 1,25-di-
hydroxy vitamin D3 [1,25(OH)2D3] are considered to be the 
endocrine regulators of calcium homeostasis. PTH secretion, 
which is triggered by hypocalcemia, increases extracellular 
calcium levels by stimulating bone resorption, renal reabsorp-
tion, and intestinal calcium absorption indirectly through the 
synthesis of 1,25(OH)2D3 in the kidney.12 Due to their role in 
the control of calcium levels, PTH and 1,25(OH)2D3 have re-
ceived much attention. However, the exact roles of these in-
trinsic factors in urolithiasis remain to be elucidated. The aim 
of this study was to find the association between PTH or 
1,25(OH)2D3 and serum and urinary metabolites and the cor-
relation between PTH or 1,25(OH)2D3 and urinary calcium 
excretion in calcium stone formers (SFs).
MATERIALS AND METHODS
　　　
Patients
Between 2009 and 2011, 326 calcium SFs (male: 204, fe-
male: 122) with informed consent agreement were enrolled. 
Pediatric patients (<16 years) and patients with incomplete 
24 hour urine collection, impaired renal function (serum 
creatinine >1.5 mg/dL), infection stones, radiolucent stones, 
malformation of the urological system, hypercalcemia, pri-
or bowel surgery, or a prior diagnosis of primary hyper-
parathyroidism or other systemic diseases (any cancer, al-
coholic liver disease and osteoporosis drug medication like 
calcium pills etc.), that might affect calcium and bone me-
tabolism were excluded. Controls were selected with simi-
lar age and gender proportions to the calcium SFs, and sub-
jects were screened to ensure that they were within the 
normal range of all laboratory findings and had no history 
of urinary stone. The Ethics Committee of our institution 
approved this protocol. The collection and analysis of all 
samples was approved by the Institutional Review Board of 
our institution. The data collected included the history of 
kidney stones and medications, and a metabolic evaluation 
such as 24-hour urinary and fasting serum biochemistry as 
well as intact PTH and 1,25(OH)2D3 which was performed 
at the same time. Intact PTH was measured with an immu-
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24 h urinary magnesium (r=-0.116, p=0.036) and calcium 
excretion (r=-0.193, p<0.001). In the multiple linear regres-
sion analysis, PTH level was inversely correlated with 24 h 
urinary calcium excretion (β=-0.188, p<0.001) (Table 1).
Comparison of clinical characteristics and serum 
parameters according to calciuria and stone episodes
There were no significant differences in parameters such as 
age, serum calcium, phosphate and uric acid between the hy-
percalciuria group and the normocalciuria group, or between 
first SFs and recurrent SFs. The serum 1,25(OH)2D3 level 
was significantly higher in the hypercalciuric group and re-
current SFs than in the normocalciuric group and first SFs 
(p<0.001, p=0.050, respectively). However, there were no 
significant differences in PTH levels between these groups 
(p=0.295, 0.256, respectively) (Table 2). 
Univariate and multivariate analysis for the 
relationship between urinary calcium excretion and 
other parameters   
Urinary calcium excretion was positively correlated with 
BMI (r=0.149, p=0.007), stone episodes (r=0.151, p=0.006), 
1,25(OH)2D3 level (r=0.347, p<0.001), 24 h urine total vol-
RESULTS
 
Clinical and laboratory parameters for the study 
populations
The mean age of the study population was 45.8±12.3 years 
and the mean body mass index (BMI) was 24.5±3.4 kg/m2. 
The mean serum calcium, phosphate, uric acid, PTH, and 
1,25(OH)2D3 were 9.49±0.49 mg/dL, 3.61±0.62 mg/dL, 
5.65±1.52 mg/dL, 28.0±14.4 pg/mL, and 52.5±19.0 ng/mL, 
respectively. 
 
Relationship between 1,25(OH)2D3 or PTH and clinico-
laboratory parameters
1,25(OH)2D3 levels were positively correlated with 24 h 
urinary phosphate (r=0.120, p=0.030), uric acid (r=0.158, 
p=0.004), pH (r=0.170, p=0.002), and calcium excretion 
(r=0.347, p<0.001). However, in the multiple linear regres-
sion analysis, the 1,25(OH)2D3 level was correlated signifi-
cantly only with 24 h urine calcium excretion (β=0.355, 
p<0.001). 
PTH was positively correlated with age (r=0.146, p=0.008) 
and sex (r=0.148, p=0.008), but inversely correlated with 
Table 1. Relationships between Serum 1,25(OH)2D3 or PTH Levels and Clinical and Laboratory Parameters
Serum 1,25(OH)2D3 Serum PTH
Spearman correlation Linear regression Spearman correlation Linear regression
R p value β p value R p value β p value
Age -0.026 0.643 0.146 0.008 0.088 0.117
Sex (male/female) -0.025 0.652 0.148 0.008 0.102 0.068
BMI 0.015 0.789 0.028 0.614
Family history 0.048 0.391 0.008 0.893
Stone episode 0.108 0.051 -0.019 0.735
Serum
    Sodium -0.005 0.928 0.107 0.054
    Calcium 0.069 0.212 -0.067 0.226
    Phosphate -0.057 0.303 -0.012 0.834
    Uric acid -0.067 0.228 0.019 0.730
    PTH/1,25(OH)2D3 -0.021 0.710 -0.021 0.710
24 hrs urine
    Total volume 0.035 0.529 -0.059 0.292
    Sodium 0.069 0.217 0.040 0.470
    Calcium 0.347 <0.001 0.355 <0.001 -0.193 <0.001 -0.188 <0.001
    Phosphate 0.120 0.030 -0.081 0.256 -0.085 0.126
    Magnesium -0.072 0.197 -0.116 0.036 -0.038 0.494
    Citrate -0.024 0.667 -0.053 0.339
    Oxalate -0.081 0.144 0.031 0.577
    Uric acid 0.158 0.004 -0.003 0.971 -0.062 0.261
    pH 0.170 0.002 0.101 0.062 -0.095 0.087
1,25(OH)2D3, 1,25-dihydroxy vitamin D3; PTH, parathyroid hormone; BMI, body mass index; pH, potential of hydrogen.
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DISCUSSION
In the present study, an assessment of the roles of 1,25(OH)2 
D3 and PTH in calcium stone formers revealed a correlation 
between 1,25(OH)2D3 and PTH levels and urinary calcium 
excretion. 1,25(OH)2D3 levels were significantly increased 
in calcium SFs compared to controls, and the balance be-
tween 1,25(OH)2D3 and PTH was altered in calcium SFs.  
Hypercalciuria is the most common metabolic abnormali-
ty in patients with urolithiasis.10 Calcium oxalate overgrowth 
on plaque is due to calcium oxalate supersaturation, which is 
strongly linked to hypercalciuria.13 The present data show-
ing a strong correlation between serum 1,25(OH)2D3 and 
PTH levels and urinary calcium excretion suggested that 
urinary calcium excretion might be affected by intrinsic 
factors such as serum 1,25(OH)2D3 and PTH, as well as en-
vironment factors such as sodium intake. 
Calcium regulates a wide range of biological processes and 
is one of the principal constituents of bone. The maintenance 
of adequate concentrations of calcium in the extracellular flu-
id requires the activity of two hormones, 1,25(OH)2D3 and 
PTH.12 PTH, which functions through a negative feedback 
loop to regulate extracellular calcium levels, is secreted in 
response to hypocalcemia and stimulates the release of cal-
cium from bone, decreases the urinary loss of calcium, and 
indirectly stimulates calcium absorption in the small intes-
tine by stimulating the synthesis of 1,25(OH)2D3.12 
The relationship between 25(OH) vitamin D3 (calcidiol) 
ume (r=0.305, p<0.001), urinary sodium (r=0.502, p<0.001), 
phosphate (r=0.469, p<0.001), magnesium (r=0.375, p< 
0.001), citrate (r=0.277, p<0.001), uric acid excretion (r= 
0.553, p<0.001), and pH (r=0.170, p=0.002), but was inverse-
ly correlated with serum PTH level (r=-0.193, p<0.001). To 
evaluate the association between 24 h urinary calcium ex-
cretion and serum vitamin D3 or PTH after adjusting for the 
effects of other parameters, multiple linear regression analy-
sis was performed using parameters correlated with urinary 
calcium excretion in Pearson correlation. Stone episodes 
(β=0.083, p=0.045), serum 1,25(OH)2D3 (β=0.259, p<0.001) 
and PTH (β=-0.160, p<0.001) levels, and urinary sodium 
(β=0.270, p<0.001), phosphate (β=0.192, p<0.001) and uric 
acid (β=0.243, p<0.001) levels, were significantly associated 
with calcium excretion (Table 3). The patients in highest 
tertile of 1,25(OH)2D3 had a more than 3.1 fold risk of hy-
percalciuria than those in the lowest tertile (OR=3.14, 95% 
CI: 1.431--6.888, p=0.004) (Table 4).
Relationship between 1,25(OH)2D3 and PTH in calcium 
SFs vs. controls
The mean PTH and 1,25(OH)2D3 were 28.0±14.4 pg/mL, 
52.5±19.0 ng/mL in calcium SFs and 27.8±10.8 pg/mL, 
18.4±7.3 ng/mL in controls (p=0.871, p<0.001, respective-
ly). 1,25(OH)2D3 levels were significantly higher in calcium 
SFs than in controls (p<0.001). No correlation was found 
between 1,25(OH)2D3 and PTH in calcium SFs (R=0.005, 
p=0.929). In controls, the 1,25(OH)2D3 levels were inversely 
correlated with PTH levels (R=-0.269, p=0.001) (Fig. 1).
Table 2. Comparison of Clinical Characteristics and Serum Parameters According to Calciuria and Stone Episodes
According to calciuria According to stone episodes
NC (n=274) HC (n=52) p value FSF (n=185) RSF (n=139) p value
No. gender (%) 0.044 0.109
    M    178 (65.0)    26 (50.0)   109 (58.9)   94 (67.6)
    F      96 (35.0)    26 (50.0)     76 (41.1)   45 (32.4)
Age (yrs)     45.4±12.5     47.9±10.9 0.176     45.4±13.0     46.3±11.5 0.527
Body height (cm) 164.6±8.2 163.2±9.9 0.282 163.9±8.6 164.9±8.3 0.297
Body weight (kg)     65.6±10.8     69.4±13.0 0.022     65.1±11.5     67.7±10.8 0.041
BMI (kg/m2)   24.2±3.3   26.0±3.8 <0.001   24.2±3.6   24.8±3.1 0.096
Serum
    Creatinine     1.01±0.21     0.93±0.16 0.007     1.00±0.21     1.01±0.20 0.623
    Calcium (mg/dL)     9.46±0.49     9.60±0.49 0.058     9.45±0.52     9.53±0.44 0.151
    Phosphate (mg/dL)     3.60±0.60     3.63±0.74 0.798     3.65±0.64     3.56±0.60 0.183
    Uric acid (mg/dL)     5.70±1.50     5.39±1.57 0.174     5.61±1.56     5.70±1.47 0.605
    PTH (pg/mL)     28.3±14.7     26.1±12.2 0.295     28.7±16.1     26.9±11.6 0.256
    1,25(OH)2D3 (ng/mL)     50.8±17.9     61.3±21.9 <0.001     50.7±17.8     54.8±20.3 0.050
NC, normocalciuria; HC, hypercalciuria; FSF, first stone former; RSF, recurrent stone former; No, number; M, male; F, female; BMI, body mass index; PTH, 
parathyroid hormone; 1,25(OH)2D3, 1,25-dihydroxy vitamin D3. 
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renal SFs were higher than in the control groups. 
PTH stimulates the metabolism of 1,25(OH)2D3 to its ac-
tive hormonal form, 1,25(OH)2D3 in the kidney. 1,25(OH)2D3 
promotes the absorption of calcium in the small intestine 
and calcium resorption in bone.20 Although the functions of 
1,25(OH)2D3 and PTH are closely associated, a correlation 
between the levels of 1,25(OH)2D3 and PTH was not ob-
served in the current study. Alterations in the balance be-
tween PTH and 1,25(OH)2D3 could be an important factor 
in calcium stone formation in calcium SFs.
PTH also correlated negatively with urinary calcium ex-
cretion. However, based on the exclusion of patients with 
hyperparathyroidism, this correlation was considered to be 
part of the normal process of homeostasis of hypercalciuria. 
Hess and Jaeger18 reported that primary intestinal hyperab-
levels and hypercalciuria has been reported previously.14,15 
However, some studies reported a weak correlation between 
calcium excretion and the level of 25(OH) vitamin D3.16 In 
reality, 1,25(OH)2D3 is considered to be more important 
compared to 25(OH)D3 for mediating the biological actions 
of vitamin D on calcium and bone metabolism.17 In the pres-
ent study, a strong relationship between 1,25(OH)2D3 and 
urinary calcium excretion was observed. Moreover, the hy-
percalciuric group had higher levels of 1,25(OH)2D3 than the 
normocalciuric group. Hess and Jaeger18 reported that pa-
tients with idiopathic hypercalciuria had higher serum con-
centrations of 1,25(OH)2D3 than normocalciuric SFs. Fur-
thermore, in the present study, 1,25(OH)2D3 was significantly 
increased in calcium SFs compared to controls. Shakhssalim, 
et al.19 also reported that the serum 1,25(OH)2D3 levels in 
Table 3. Relationships between Urinary Calcium Excretion and Clinical and Laboratory Parameters
Spearman correlation Linear regression
Correlation (r) p value Standard coefficient p value
Age (yrs) -0.065   0.241
Sex (male/female) -0.069   0.213
BMI (kg/m2)  0.149   0.007 -0.024   0.572
Family history  0.012   0.831
Stone episode  0.151   0.006  0.083   0.045
Serum
    Sodium  0.030   0.595
    Calcium  0.086   0.120
    Phosphate -0.020   0.715
    Uric acid -0.054   0.331
    1,25(OH)2D3  0.347 <0.001  0.259 <0.001
    PTH -0.193 <0.001 -0.160 <0.001
24 hrs urine
    Total volume  0.305 <0.001 -0.051   0.292
    Sodium  0.502 <0.001  0.270 <0.001
    Phosphate  0.469 <0.001  0.192 <0.001
    Magnesium  0.375 <0.001  0.039   0.346
    Citrate  0.277 <0.001  0.073   0.106
    Oxalate -0.019   0.727
    Uric acid  0.553 <0.001  0.243 <0.001
    pH  0.170   0.002  0.027   0.525
BMI, body mass index; 1,25(OH)2D3, 1,25-dihydroxy vitamin D3; PTH, parathyroid hormone; pH, potential of hydrogen.
Table 4. Results of Logistic Regression in Calcium Stone Formers Considering Hypercalciuria as the Dependent Variable Ac-
cording to Tertiles of Serum 1,25(OH)2D3 as the Independent Variable 
1,25(OH)2D3 (ng/mL) Normocalciuria (n=274) Hypercalciuria (n=52) OR (95% CI) p value
Mean±SD 50.8±17.9 61.3±21.9 <0.001
≤42.2 99 (36.1)    10 (19.2) 1
>42.2 to  ≤58.9 93 (34.0)    16 (30.8) 1.703 (0.736--3.942)   0.214
>58.9 82 (29.9) 26 (50) 3.139 (1.431--6.888)   0.004
Ptrend   0.003
1,25(OH)2D3, 1,25-dihydroxy vitamin D3; ORs, odds ratios; CI, confidence interval; SDs, standard deviations.
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considered to be insignificant. Second, occupation and sea-
sonal variation were not considered in this study despite the 
importance of the effect of skin exposure to sunlight on 
1,25(OH)2D3 levels. Parry and Lister23 reported increased ex-
posure to sunlight as the most likely cause of hypercalciuria. 
Third, This study was performed by cross-sectional manner 
and therefore, causality cannot be determined. It may be the 
idiopathic hypercalciuria which is causing the increasing the 
1,25(OH)2D3, and not the other way around. However, this 
would be unlikely seen from our result that PTH was actual-
ly negatively associated with urinary calcium excretion. Fi-
nally, these results alone cannot reach the mechanism by 
what calcium SFs have elevated 1,25(OH)2D3 and future 
studies will need to be considered.   
In conclusion, the present study is the first to examine the 
relationship between serum 1,25(OH)2D3 and PTH in calci-
um SFs. 1,25(OH)2D3 was closely correlated with urinary 
calcium excretion levels. Increased 1,25(OH)2D3 levels were 
observed in the hypercalciuric group as well as in recurrent 
SFs. In calcium SFs, the 1,25(OH)2D3 level was high and 
was not correlated with PTH levels. These findings suggest 
that 1,25(OH)2D3 might be an important intrinsic factor in 
calcium stone formation. 
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sorption of calcium led to the depression of PTH secretion 
and PTH level was lower in hypercalciuric SFs compared 
to normocalciuric SFs at the same blood Ca2+ levels.21 Sim-
ilarly, PTH was lower in hypercalciuric SFs than in normo-
calciuric SFs in the current study, although the difference 
between the two groups did not reach statistical signifi-
cance. 
In the present study, multiple regression analysis revealed 
a positive correlation between 1,25(OH)2D3 and urinary 
calcium excretion. Shakhssalim, et al.19 also reported that 
1,25(OH)2D3 was an important hormone in the pathogene-
sis of recurrent renal calcium stone disease and could in-
crease the risk of renal stone development by increasing 
urinary calcium and phosphorus excretion. However, no 
studies addressing the correlation between 1,25(OH)2D3 
and PTH in calcium SFs have been published to date. In 
our study, 1,25(OH)2D3 level was positively correlated with 
urinary calcium excretion and higher in calcium SFs than in 
controls. However, the association between 1,25(OH)2D3 
and PTH in calcium SFs was not found. Presumably, these 
findings suggest that altered regulation of 1,25(OH)2D3 
rather than PTH might be the primary intrinsic factor for 
pathogenesis in calcium SFs. 
There are several limitations to the present study. First, ab-
sorptive, renal induced, and resorptive hypercalciuria are 
common types of hypercalciuria.22 The exclusion of patients 
with primary hyperparathyroidism from the study resulted 
in the exclusion of resorptive hypercalciuria. However, renal 
induced hypercalciuria could not be excluded because we 
did not perform a calcium load test. Nevertheless, due to 
the low prevalence of renal hypercalciuria, the difference is 
Fig. 1. Correlation between 1,25(OH)2D3 and PTH (A) in calcium stone formers and (B) in controls. 1,25(OH)2D3, 1,25-dihydroxy vitamin D3; PTH, parathyroid 
hormone.
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